PSMA - 1007
Prostate cancer is the third leading cause of death from cancer among Canadian men. To increase the number of prostate cancer-specific diagnostic agents in Canada, CPDC is sponsoring a Phase III
clinical trial of [18F]PSMA-1007. The agent targets prostate specific membrane antigen (PSMA) protein which is overexpressed in prostate cancer.
CPDC holds exclusive licensing rights for PSMA-1007 from ABX GmbH (Radeberg, Germany) to manufacture, commercialize and distribute the imaging agent in Canada. Through a sublicensing manufacturing agreement with Lawson Health Research Institute (London, Canada), CPDC is focused on bringing a critically important diagnostic tool for prostate cancer to the Canadian market.
CPDC’s Phase 3 clinical trial (CPD-002) is a prospective, single arm, non-randomized, open label study of 100 men with suspected persistent or recurrent prostate cancer based on detectable levels of prostate serum antigen (PSA). Patient enrollment began in 2021 and the trial concluded Q4 2023. CPDC aims to have Health Canada approval by Q4 2025.
For additional information about the clinical trial, visit www.clinicaltrials.gov (NCT04644822)
